ASAM Joins Letter Calling to End $75 Contingency Management Restriction

On December 13, ASAM and fellow healthcare stakeholder groups sent a letter to the Biden administration calling for an end to the current $75 maximum restriction in certain federal grant programs on patient incentives for contingency management (CM).

In the absence of FDA-approved medications for stimulant use disorders, CM, a behavioral therapy that provides tangible incentives to patients who demonstrate positive behaviors, has emerged as the standard of care. The letter argues that the current $75 cap on such incentives undermines the effectiveness of and access to this treatment.

Read the letter here.